Study to Assess GTAEXS617 in Patients With Advanced Solid Tumors
A phase 1/2 study to assess the safety, tolerability, pharmacokinetics and anti-tumor activity of GTAEXS617-001 in patients with advanced solid tumors.
Advanced Solid Tumor
DRUG: GTAEXS617
Module 1 Part A: To characterize the safety profile of GTAEXS617 as monotherapy, Incidence of treatment-emergent adverse events (TEAEs), characterised by type, incidence, severity (graded by NCI CTCAE v5.0), seriousness, timing and relationship to GTAEXS617 dosing., Through patient study completion, an average of 6 months|Module 1 Part A: To characterize the Dose Limiting Toxicities (DLTs) of GTAEXS617 as monotherapy, Incidence of dose limiting toxicities (DLTs) during Cycle 1 of treatment., Through patient study completion, an average of 6 months|Module 1 Part A: To establish the Recommended Phase 2 Dose (RP2D) of GTAEXS617 as monotherapy, The RP2D will not exceed the maximum tolerated dose (MTD) if established., Through study completion for all patients in Module 1 Part A. Estimated 18 months.|Module 1 Part B: To characterize the safety profile of GTAEXS617 in combination with selected Standard of Care (SoC) regimens, Incidence of treatment-emergent adverse events (TEAEs), characterised by type, incidence, severity (graded by NCI CTCAE v5.0), seriousness, timing and relationship to GTAEXS617 dosing., Through patient study completion, an average of 6 months|Module 1 Part B: To characterize the Dose Limiting Toxicities (DLTs) of GTAEXS617 in combination with selected Standard of Care (SoC) regimens, Incidence of dose limiting toxicities (DLTs) during Cycle 1 of treatment, Through patient study completion, an average of 6 months
Module 1 Part A: GTAEXS617 Maximum Plasma Concentration (Cmax), Maximum Plasma Concentration (Cmax) when GTAEXS617 administered as monotherapy, Through patient study completion, an average of 6 months|Module 1 Part A: GTAEXS617 Time Maximum Plasma Concentration (Tmax), Time Maximum Plasma Concentration (Tmax) when GTAEXS617 administered as monotherapy, Through patient study completion, an average of 6 months|Module 1 Part A: GTAEXS617 Area under Plasma Concentration Curve during 24 hour dosing interval (AUC 0-tau), Area under Plasma Concentration Curve during 24 hour dosing interval (AUC 0-tau) when GTAEXS617 administered as monotherapy, Through patient study completion, an average of 6 months
A phase 1/2 study to assess the safety, tolerability, pharmacokinetics and anti-tumor activity of GTAEXS617-001 as monotherapy and in combination, in patients with one of the following advanced solid tumors: head and neck squamous cell carcinoma, colorectal adenocarcinoma, pancreatic adenocarcinoma, non-small cell lung cancer, breast cancer (HR+ and HER2- that has progressed to a prior treatment with CD4/CDK6 inhibitor), ovarian epithelial carcinoma.